15/11/2024  08:13:34 Chg. +0.440 Volume Bid20:55:35 Demandez à20:55:35 Capitalisation boursière Dividende Y. Rapport P/E
45.060EUR +0.99% 0
Chiffrre d'affaires: 0.000
-Bid taille: - -Ask la taille: - 4.77 Mrd.EUR 3.63% 28.96

Description de l'entreprise

Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
 

Conseil d'administration & Conseil de surveillance

PDG
Liisa Hurme
Conseil d'administration
Jari Karlson, Outi Vaarala, Satu Ahomäki, Virve Laitinen, Juhani Kankaanpää, Olli Huotari
Conseil de surveillance
Mikael Silvennoinen, Ari Lehtoranta, Eija Ronkainen, Hilpi Rautelin, Kari Jussi Aho, Veli-Matti Mattila, Maziar Mike Doustdar, Karen Lykke Sørensen
 

Données de l'entreprise

Nom: Orion Corporation
Adresse: Orionintie 1A,FI-02200 Espoo
Téléphone: +358-10-4261
Fax: -
Courriel: -
Internet: is.gd/3PivOU
Industrie: Healthcare
Secteur: Healthcare Providers
Sous-secteur: Healthcare Providers
Fin de l'exercice financier: 31/12
Flotte libre: 97.66%
IPO date: -

Relations avec les investisseurs

Nom: Jari Karlson
Téléphone IR: +358-10-426-2883
IR-Fax: -
E-mail IR: -